Latest news
{{'2025-11-14T14:21:15Z' | dateFormatFilter}}
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
{{'2025-11-13T22:38:30Z' | dateFormatFilter}}
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
{{'2025-11-10T13:45:00Z' | dateFormatFilter}}
Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
